Shanghai SIMR Biotechnology Co.,Ltd

中文 | EN

中文 EN

Expanded Access Policy Press Releases

Home > MEDIA > Press Releases

Press Releases

Expanded Access Policy

16 2024-09

First Patient Enrolled in Phase 2 Clinical Trial of SR750 fo

Shanghai, China – [September 16th, 2024] – SIMR Biotech announces the enrollment...
11 2024-09

First Patient Enrolled in Phase 2 Clinical Trial of SR1375 i

On 11th September 2024, Shanghai SIMR Biotechnology Co., Ltd. announced that the...
03 2023-01

Milestone - SR1375'S Phase II Clinical Trial Approved by th

On December 13, 2022，Shanghai SIMR Biotechnology Co., Ltd announced that, the candidate drug SR1375 with a new mechanism of action for the treatment of acute inflammation solely developed by the compa...
12 2022-11

Shanghai SIMR Biotech received 150 million Chinese Yuan C1 r

On November 8, 2022, Shanghai SIMR Biotech (here in after referred to as "SIMR Bio " or the "Company") announced that it has obtained a C1 round of financing of 150 million Chinese...
17 2021-12

Milestone of SIMR —— The first Phase II clinical study for S

On 17th Dec 2021, Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company”) announced that company’s investigational drug SR419, the first asset of SIMR e...
01 2021-11

Milestone - SR1375'S Phase II Clinical Trial Approved by the

Shanghai, China, Nov 1,2021 ---- Shanghai SIMR Biotechnology Co., Ltd. (here in after referred to as "SIMR" or "Company") initiated the first-in-human study of candidate drug SR750...

Home Previous 1 2 3 Next Last

Previous Next Road 3 page 15 strip